当前位置：药药网 / 药品 / 美国NDC复合药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 报告期内： -格式:2020-5-3
NDC包装id： 市场分类： 活性成分： 持证企业：
 美国NDC复合药物数据库文件4843条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
报告期内
活性成分
市场分类
规格(分析)
NDC包装id
Ketamine
HUMAN COMPOUNDED DRUG
71449-068
Denver Solutions, LLC dba Leiters Health
2024-2
KETAMINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
71449-068-11
Ketamine
HUMAN COMPOUNDED DRUG
71449-068
Denver Solutions, LLC dba Leiters Health
2024-2
KETAMINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL
71449-068-32
Trophamine 6% / Dextrose 10% With Calcium Gluconate 3.75mEq and Heparin 125 units 250ml in 250ml bag
HUMAN COMPOUNDED DRUG
72196-0423
Central Admixture Pharmacy Services, Inc.
2024-2
LEUCINE; METHIONINE; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE; HEPARIN SODIUM; LYSINE ACETATE; SERINE; GLUTAMIC ACID; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; CALCIUM GLUCONATE MONOHYDRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2.1 g/250 mL; .51 g/250 mL; 1.02 g/250 mL; .48 g/250 mL; 1.23 g/250 mL; .81 g/250 mL; .54 g/250 mL; .72 g/250 mL; .3 g/250 mL; 1.17 g/250 mL; 125 U/250 mL; 1.8 g/250 mL; .57 g/250 mL; .75 g/250 mL; .066 g/250 mL; .36 g/250 mL; .63 g/250 mL; .036 g/250 mL; .72 g/250 mL; 1.8 g/250 mL; .0375 g/250 mL; 25 g/250 mL; 3.75 meq/250 mL
72196-0423-1
Trophamine 3% / Dextrose 10% 250ml in 250ml bag
HUMAN COMPOUNDED DRUG
71285-0404
Central Admixture Pharmacy Services, Inc.
2024-2
GLUTAMIC ACID; LYSINE ACETATE; SERINE; TYROSINE; N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.375 g/250 mL; .9 g/250 mL; .285 g/250 mL; .033 g/250 mL; .18 g/250 mL; .315 g/250 mL; .018 g/250 mL; .36 g/250 mL; .9 g/250 mL; .01875 g/250 mL; 25 g/250 mL; 1.05 g/250 mL; .255 g/250 mL; .51 g/250 mL; .24 g/250 mL; .615 g/250 mL; .405 g/250 mL; .27 g/250 mL; .36 g/250 mL; .15 g/250 mL; .585 g/250 mL
71285-0404-1
Trophamine 3.5% / Dextrose 10% With Calcium Gluconate 3.75 mEq 250ml in 250ml bag
HUMAN COMPOUNDED DRUG
71285-0407
Central Admixture Pharmacy Services, Inc.
2024-2
N-ACETYLTYROSINE; THREONINE; CYSTEINE HYDROCHLORIDE; HISTIDINE; ARGININE; TAURINE; DEXTROSE MONOHYDRATE; LEUCINE; METHIONINE; GLUTAMIC ACID; PROLINE; ASPARTIC ACID; ISOLEUCINE; ALANINE; GLYCINE; PHENYLALANINE; TRYPTOPHAN; VALINE; CALCIUM GLUCONATE MONOHYDRATE; LYSINE ACETATE; SERINE; TYROSINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.21 g/250 mL; .3675 g/250 mL; .021 g/250 mL; .42 g/250 mL; 1.05 g/250 mL; .021875 g/250 mL; 25 g/250 mL; 1.225 g/250 mL; .2975 g/250 mL; .4375 g/250 mL; .595 g/250 mL; .28 g/250 mL; .7175 g/250 mL; .4725 g/250 mL; .315 g/250 mL; .42 g/250 mL; .175 g/250 mL; .6825 g/250 mL; 3.75 meq/250 mL; 1.05 g/250 mL; .3325 g/250 mL; .0385 g/250 mL
71285-0407-1
Vancomycin 1gm added to NS
HUMAN COMPOUNDED DRUG
71285-6064
Central Admixture Pharmacy Services, Inc.
2024-2
VANCOMYCIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1 g/250 mL
71285-6064-1
Vancomycin 750mg added to NS
HUMAN COMPOUNDED DRUG
71285-6071
Central Admixture Pharmacy Services, Inc.
2024-2
VANCOMYCIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
750 mg/250 mL
71285-6071-1
Vancomycin 1.25gm added to D5W
HUMAN COMPOUNDED DRUG
71285-6073
Central Admixture Pharmacy Services, Inc.
2024-2
VANCOMYCIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
1.25 g/250 mL
71285-6073-1
Biest 50/50 0.45mg/testosterone 0.4mg/gm
HUMAN COMPOUNDED DRUG
26436-5623
Hybrid Pharma
2024-2
ESTRIOL; TESTOSTERONE; ESTRADIOL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
.225 mg/1 g; .4 mg/1 g; .225 mg/1 g
26436-5623-4
DILTIAZEM 2%
HUMAN COMPOUNDED DRUG
26436-5628
Hybrid Pharma
2024-2
DILTIAZEM HCL
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 mg/1 g
26436-5628-6
LIDOCAINE/TETRACAINE/ PHENYLEPHRINE HCL 20/7/0.5
HUMAN COMPOUNDED DRUG
26436-5624
Hybrid Pharma
2024-2
TETRACAINE; LIDOCAINE; PHENYLEPHRINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
70 mg/1 g; 200 mg/1 g; 5 mg/1 g
26436-5624-1
LIDOCAINE/TETRACAINE/ BUPIVACAINE HCL 20/7/3
HUMAN COMPOUNDED DRUG
26436-5625
Hybrid Pharma
2024-2
TETRACAINE; LIDOCAINE; BUPIVACAINE HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
70 mg/1 g; 200 mg/1 g; 30 mg/1 g
26436-5625-1
BENZOCAINE 20
HUMAN COMPOUNDED DRUG
26436-5621
Hybrid Pharma
2024-2
BENZOCAINE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
200 mg/1 g
26436-5621-1
Naltrexone HCL 2mg
HUMAN COMPOUNDED DRUG
26436-5629
Hybrid Pharma
2024-2
NALTREXONE HYDROCHLORIDE DIHYDRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
2 mg
26436-5629-1
Moxifloxacin 0.5%, Bromfenac 0.075%
HUMAN COMPOUNDED DRUG
83826-9034
OSRX, Inc.
2024-2
MOXIFLOXACIN HYDROCHLORIDE; BROMFENAC SODIUM
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL; 75 mg/1 mL
83826-9034-5
Tropicamide 1%, Phenylephrine HCl 2.5%
HUMAN COMPOUNDED DRUG
83826-9057
OSRX, Inc.
2024-2
PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
25 mg/1 mL; 10 mg/1 mL
83826-9057-2
Dexamethasone phosphate 0.1%, Moxiflocacin HCl 0.5%
HUMAN COMPOUNDED DRUG
83826-9004
OSRX, Inc.
2024-2
MOXIFLOXACIN HYDROCHLORIDE; DEXAMETHASONE SODIUM PHOSPHATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL; 1 mg/1 mL
83826-9004-1
Prednisolone Phosphate 1%, Moxifloxacin 0.5%
HUMAN COMPOUNDED DRUG
83826-9033
OSRX, Inc.
2024-2
PREDNISOLONE SODIUM PHOSPHATE; MOXIFLOXACIN HYDROCHLORIDE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
10 mg/1 mL; 5 mg/1 mL
83826-9033-5
Brimonidine Tartrate 0.1%, Dorzolamide 2%
HUMAN COMPOUNDED DRUG
83826-9059
OSRX, Inc.
2024-2
DORZOLAMIDE HYDROCHLORIDE; BRIMONIDINE TARTRATE
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
20 mg/1 mL; 1 mg/1 mL
83826-9059-2
Prednisolone Phosphate 1%, Moxifloxacin 0.5%, Bromfenac 0.075%
HUMAN COMPOUNDED DRUG
83826-9014
OSRX, Inc.
2024-2
MOXIFLOXACIN HYDROCHLORIDE; PREDNISOLONE SODIUM PHOSPHATE; BROMFENAC SODIUM
OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
5 mg/1 mL; 10 mg/1 mL; .75 mg/1 mL
83826-9014-5
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3